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Bardet–Biedl syndrome is a rare ciliopathy characterized by retinal
dystrophy, obesity, intellectual disability, polydactyly, hypogonadism and
renal impairment. Patients are at high risk of cardiovascular disease.
Mutations in BBS1 and BBS10 account for more than half of those with
molecular confirmation of the diagnosis. To elucidate genotype–phenotype
correlations with respect to cardiovascular risk indicators 50 patients with
mutations in BBS1 were compared with 19 patients harbouring BBS10
mutations. All patients had truncating, missense or compound
missense/truncating mutations. The effect of genotype and mutation type
was analysed. C-reactive protein was higher in those with mutations in
BBS10 and homozygous truncating mutations (p= 0.013 and p= 0.002,
respectively). Patients with mutations in BBS10 had higher levels of C
peptide than those with mutations in BBS1 (p= 0.043). Triglyceride levels
were significantly elevated in patients with homozygous truncating
mutations (p= 0.048). Gamma glutamyl transferase was higher in patients
with homozygous truncating mutations (p= 0.007) and heterozygous
missense and truncating mutations (p= 0.002) than those with homozygous
missense mutations. The results are compared with clinical cardiovascular
risk factors. Patients with missense mutations in BBS1 have lower
biochemical cardiovascular disease markers compared with patients with
BBS10 and other BBS1 mutations. This could contribute to stratification of
the clinical service.
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Bardet–Biedl syndrome (BBS) is a pleiotropic auto-
somal recessive ciliopathy characterized by retinal
dystrophy, post-axial polydactyly, obesity, learning
difficulties, hypogonadism and renal dysfunction (1,
2). There is a high prevalence of cardiovascular,
endocrine and renal disorders among patients with
BBS (3). In order to optimize the clinical man-
agement, it is imperative to identify patients who
are most at risk of disease-associated morbidity and
mortality.
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This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited.
Forsythe et al.
Since the clinical criteria for a diagnosis were pro-
posed, 19 genes (BBS1–BBS19) have been discovered
(4, 5). BBS genes code for proteins that localize to the
basal body of the cilium.Mutations lead to defective cilia
accounting in part for the variable effects observed in
BBS. A clinical diagnosis can be confirmed by sequenc-
ing the known disease-causing genes in 80% of patients
(authors’ own unpublished data).
The majority of pathogenic mutations are found
in BBS1 and BBS10 accounting for 23.2% and 20%,
respectively in populations of northern European
descent (4). The commonest mutation is M390R found
in 82.5% of a cohort of British patients with BBS1
mutations (4). The frameshift mutation C91LfsX5
is prevalent in patient populations with BBS10
mutations.
Variable phenotypic expressivity is a hallmark of BBS,
however, even among patients with the same genotype,
interfamilial and intrafamilial phenotypic variability is
common. Mutations in other BBS genes may modify
the phenotype, accounting for this variability (6). Several
studies have attempted to identify a genotype–phenotype
correlation in BBS (7–10). These have primarily focused
on physical features and have been limited by small
sample sizes or participants from the same kindred.
This is the first study to explore the correlation between
genotype, mutation type and morbidity in BBS. We
examine indicators of cardiovascular, metabolic and
renalmorbidity in a large cohort of patients with BBS and
compare the two most commonly mutated genes: BBS1
and BBS10.
Methods
Patients
Two hundred and thirty nine patients attending the
national Bardet-Biedl Syndrome clinics in London and
Birmingham were assessed for height, weight, blood
pressure, BBS mutation analysis, full blood count,
renal function, liver function, inflammatory markers,
endocrine and lipid profile. Information on cardiovas-
cular risk factors was collected retrospectively from
patient notes. The following clinical parameters were
ascertained: (i) hypertension (defined as a blood pres-
sure over 140/90 or normotensive requiring antihyper-
tensivemedication), (ii) hypercholesterolaemia requiring
hypolipidaemic agents, (iii) diabetes mellitus requiring
hypoglycaemic medication, (iv) structural renal abnor-
malities and/or dialysis or renal transplant, and (v) struc-
tural cardiac abnormalities. Patients were predominantly
of Caucasian origin. Referrals were made primarily via
the British national patient support group and clinical
geneticists in the United Kingdom.
Mutation screening
Eighty four of the 239 patients had two known
pathogenic mutations in BBS genes. Of these, 73
harboured two mutations in BBS1 or BBS10. Mutation
analysis was primarily undertaken through targeted
sequencing of the four most common mutations: M390R
in BBS1, and Y24X and R275X in BBS2 and C91LfsX5
in BBS10. Where only one mutation was found, full
sequencing of the relevant gene was performed to
identify a second mutation.
Statistical analysis
Analysis was targeted to BBS1 and BBS10 patients
with truncating and/or missense mutations to allow for
adequate sample sizes.
We applied a two pronged approach to statistical anal-
ysis. Mann–Whitney U test, Kruskal–Wallis test and
analysis of variance (anova) were performed as appro-
priate to identify associations between genes (BBS1
vs BBS10) and mutation types (homozygous truncating
mutations, heterozygous missense and truncating muta-
tions or homozygous missense mutations). Multivari-
able linear regression analysis was applied to variables
which were statistically significant on univariable analy-
sis and/or known indicators of metabolic, renal and car-
diovascular disease. Statistical analyses were carried out
using spss version 21.0 (SPSS Inc., Chicago IL).
Results
Distribution of patients
Fifty two patients harboured two mutations in BBS1 and
21 harboured two mutations in BBS10. This included
nine pairs and two sets of three siblings. DNA results
were classified according to gene and mutation. Muta-
tion type was further classified according to the pre-
dicted severity. Most patients had either homozygous
missense mutations, homozygous truncating mutations
or a heterozygous missense and truncating mutations.
Two patients with BBS1mutations and two patients with
BBS10 mutations harboured splice site mutations and
were excluded from the statistical analysis. Figure 1
demonstrates the distribution of mutation types in the
BBS1 and BBS10 genotypes analysed in this study, illus-
trating the higher proportions of missense mutations in
BBS1 and truncating mutations in BBS10.
Of the remaining 69 patients seen in the clinic with a
mutation in BBS1 or BBS10 the mean age was 28.25 (SD:
14.41, range: 0–59). The mean (SD) age of patients with
a BBS1 mutation was 30.5 (15.6) years. In contrast the
mean age (SD) of patients with a mutation in BBS10 was
22.32 (8.95) years (p= 0.034). Figure 2 illustrates the age
distribution of patients with BBS1 and BBS10 included in
this study. Twenty four (48%) patients with a mutation
in BBS1 were female and 26 (52%) were male. Twelve
(63.2%) patients with mutations in BBS10 were female
and seven (36.8%) were male.
Clinical parameters
Genotype–phenotype associations were tested for
all clinical variables. Univariable analysis compar-
ing patients with BBS1 vs BBS10 demonstrated a
statistically significant difference in age, height,
344
Genetic predictors of cardiovascular morbidity in Bardet-Biedl syndrome
82% (n = 41)
10% (n = 5)
8% (n = 4)
26% (n = 5)
16% (n = 3)
58% (n = 11) Missense/ missense
Missense/ truncating
Truncating/ truncating
BBS10BBS1
Fig. 1. Distribution of mutation type in patients with BBS1 and BBS10 included in the analysis.
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Fig. 2. Age distribution of patients with mutations in BBS1 and BBS10 included in the analysis.
Table 1. Genotype–phenotype correlation: univariable comparison of statistically signiﬁcant parameters. Patients with BBS1 vs
BBS10. Only statistically signiﬁcant results are included. The full analysis is available in Tables S1, Supporting information
BBS 1 BBS 10
Mean SD Mean SD p-Valuea
Anthropomorphic measurements
Age at clinic 30.5 −15.48 22.32 −8.95 0.034
Height (cm) 163.92 −28.17 162.93 −9.31 0.031
Inﬂammatory markers
CRP (mg/l) 5.69 −2.74 9.53 −7.12 0.04
Endocrine proﬁle
C peptide (ng/ml) 1295.88 −740.13 2333.3 −1501.27 0.014
Lipid proﬁle
Triglycerides (mmol/l) 1.5 −0.73 1.98 −0.94 0.049
Renal proﬁle
Potassium (mmol/l) 4.16 −0.48 4.38 −0.42 0.015
Albumin/creatinine ratio 7.1 −22.39 5.3 −11.23 0.032
ANOVA, analysis of variance; BBS, Bardet–Biedl syndrome, CRP, C-reactive protein.
ap-Value obtained from ANOVA test or Mann–Whitney U test.
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Table 2. Mutation type-phenotype comparison: univariable comparison of statistically signiﬁcant parameters. Homozygous missense;
heterozygous truncating and missense and homozygous truncating mutations. Only statistically signiﬁcant results are included. The
full analysis is available in Table S2
Missense/missense Missense/truncating Truncating/truncating
Mean SD Mean SD Mean SD p-Valuea
Lipid proﬁle
HDL cholesterol (mmol/l) 1.28 −0.25 1.09 −0.12 1.1 −0.23 0.022
Liver proﬁle
Gamma glutamyl transferase (U/l) 29.21 −16.22 70.33 −10.02 62.75 −40.01 0.027
HDL, high-density lipoprotein.
ap-value obtained from ANOVA test or Kruskal–Wallis test.
C-reactive protein (CRP), c-peptide, triglycerides,
potassium, and albumin–creatinine ratio (Table 1).
Comparison of mutation types revealed a statistically
significant difference in high density lipoprotein (HDL)
cholesterol and gamma glutamyl transferase (GGT)
(Table 2).
We applied multivariable analysis to selected vari-
ables based on association with cardiovascular risk and
controlled for confounding factors. Statistically sig-
nificant results are displayed in Tables 3 and 4 and
discussed here.
Inﬂammatory markers
A statistically significant difference in CRP is observed.
Patients with a mutation in BBS10 or homozygous
truncating mutations have a significantly higher CRP
(p= 0.013 and p= 0.002, respectively). Analysis of
white cell count and other blood count parameters did
not reach statistical significance.
C peptide
C peptide levels were significantly higher in
patients with BBS10 compared with BBS1 mutations
(p= 0.043).
Lipid proﬁle
Triglycerides levels were significantly higher in patients
with homozygous truncating mutations (p= 0.048) than
those with other mutation types.
Liver function
Multivariable analysis demonstrated significantly higher
GGT in patients with homozygous truncating or het-
erozygous missense and truncating mutations than those
with homozygous missense mutations (p= 0.007 and
p= 0.002, respectively).
Clinical cardiovascular risk factors
Sixty seven patients had a full lipid profile, of whom 14
had hypercholesterolaemia. Hypertension was identified
in 23 of 65 patients. Fifteen of 69 patients had a diagno-
sis of diabetes mellitus. Five of 69 patients had the results
of an echocardiogram documented. Of these, one had an
Table 3. Genotype–phenotype comparison: multivariable com-
parison of selected parameters found to be statistically signif-
icant. BBS1 vs BBS10. Only statistically signiﬁcant results are
included in this table. The full analysis is available in Table S3
β estimate 95.0% CI p-Valuea
CRP (mg/l)
Genotype
BBS1 Reference – –
BBS10 4.08 (0.90, 7.25) 0.013
Age 0.06 (−0.05, 0.18) 0.295
BMI 0.1 (−0.08, 0.29) 0.266
C peptide (ng/ml)
Genotype
BBS1 Reference – –
BBS10 942.94 (32.26, 1853.61) 0.043
BMI −4.86 (−67.84, 58.12) 0.876
Blood glucose 92.08 (−71.24, 255.41) 0.258
BBS, Bardet–Biedl syndrome; BMI, body mass index; CI,
conﬁdence interval; CRP, C-reactive protein. Signiﬁcant values
are highlighted in bold.
ap-value obtained from linear regression model.
innocent murmur, two had a ventricular septal defect, one
had an atrioventricular septal defect and one patient had
aortic valve stenosis. All of these patients had two mis-
sense mutations in BBS1. Twenty nine patients had renal
ultrasounds. Sixteen of these had abnormal results rang-
ing from benign structural malformations to sonographic
evidence of chronic renal failure. Two patients had renal
transplants and one was on dialysis, all of whom had
two truncating mutations in BBS10. Figure 3a,b illustrate
the prevalence of the clinical cardiovascular risk factors.
Cardiac abnormalities are not included in these diagrams
as only five patients had documented echocardiograms
and we therefore perceive the results not be representa-
tive of the group as a whole.
Discussion
To our knowledge this is the only study comparing
cardiovascular risk factors for patients with BBS1 and
BBS10 – the two most commonly mutated genes in
patients from Europe and North America. It is the first
published study to compare the BBS phenotype accord-
ing to mutation type. Several studies have suggested that
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Table 4. Mutation type-phenotype comparison: multivariable
comparison of selected parameters found to be statistically
signiﬁcant. Homozygous missense; heterozygous truncating
and missense and homozygous truncating. Only statistically
signiﬁcant results are included in this table. The full analysis is
available as Table S4
β estimate 95.0% CI p-Valuea
CRP (mg/l)
Mutation type
Missense/missense Reference – –
Missense/truncating −0.65 (−4.42, 3.12) 0.729
Truncating/truncating 5.33 (1.99, 8.68) 0.002
Age 0.06 (−0.05, 0.17) 0.272
BMI 0.14 (−0.03, 0.31) 0.11
Triglycerides (mmol/l)
Mutation type
Missense/missense Reference – –
Missense/truncating 0 (−0.67, 0.67) 0.996
Truncating/truncating 0.56 (0.01, 1.11) 0.048
Gender
Female Reference – –
Male 0.52 (0.07, 0.98) 0.026
BMI 0.03 (0.00, 0.06) 0.05
Age −0.01 (−0.03, 0.01) 0.452
Gamma glutamyl transferase (U/l)
Mutation type
Missense/missense Reference – –
Missense/truncating 44.22 (17.90, 70.54) 0.002
Truncating/truncating 29.32 (8.72, 49.91) 0.007
Gender
Female Reference – –
Male 17.94 (4.12, 31.76) 0.013
BMI 1.05 (0.15,1.95) 0.025
Age 0.24 (−0.28, 0.76) 0.349
Signiﬁcant values are highlighted in bold.
ap-Value obtained from linear regression model.
there is little evidence of a genotype–phenotype corre-
lation in BBS and proposed that this may be because
BBS proteins contribute to a commonmolecular pathway
(4). However, there is an emerging evidence of some
genotype–phenotype correlations (7, 10). Feuillian et al.
(10) reported that patients with BBS1 had lower insulin
resistance compared with patients with BBS10. Obser-
vations from the British nationally commissioned clinic
suggest that patients with two mutations in BBS10 are
often more severely affected than those with BBS1
although there is considerable variation.
CRP increases with obesity and inflammation. Chron-
ically raised CRP indicates a higher risk of cardiovascu-
lar morbidity (11). This study shows that patients with
BBS10 genotypes and/or two truncating mutations have
a significantly worse CRP value. As CRP is a physiolog-
ical marker of inflammation and infection, it is notable
that there was no statistically significant difference in
white cell count or weight between patients with differ-
ent genes or mutation types. This suggests that patients
with missense mutations in BBS1may be at lower risk of
cardiovascular disease than patients with BBS10 or other
mutations in BBS1.
C peptide is used as a marker of insulin resistance
but has in recent years been recognized as an indepen-
dent bioactive peptide exerting effects on microvascular
function, correlating with macrovascular complications
and cardiovascular death (12). Our results demonstrate
that patients with mutations in BBS10 have significantly
higher levels of C-peptide indicating insulin resistance,
supporting the suggestion that they are at higher risk of
cardiovascular disease than patients with mutations in
BBS1.
Raised triglycerides are associated with an increased
risk of cardiovascular disease (13). Our results demon-
strate that patients with homozygous truncating muta-
tions are more likely to have raised triglycerides than
patients with other mutation types.
We demonstrated a statistically significant increase in
GGT in patients with homozygous truncating mutations
and heterozygous truncating and missense mutations
compared with patients with homozygous missense
mutations. Although used as a marker of chronic liver
disease, GGT correlates with cardiovascular diseases and
is an independent marker of cardiovascular risk (14)
making it a potentially powerful tool in the risk strati-
fication of patients with BBS.
The prevalence of clinical cardiovascular risk factors
according to genotype and mutation type do not reveal
a clear pattern. This may be because the patients in this
study are young (mean age 28.25) and the natural pro-
gression of the disease has not yet unfolded, or because
the patients with BBS1 mutations are significantly older
than the patients with mutations in BBS10. Alterna-
tively, it may reflect a true lack of genotype–phenotype
correlation.
Although analysis of renal parameters did not reveal
any statistically significant differences, it is noteworthy
that the patient on dialysis and both patients who had
received renal transplants had two truncating mutations
in BBS10. This is in keeping with previous studies
suggesting that the renal phenotype may be more severe
in patients with mutations in BBS10 (3).
The high prevalence of hypertension (Figure 3a,b)
among patients with mutations in BBS10 and two trun-
cating mutations (42% and 50%) respectively is strik-
ing considering only one person in these groups is older
than 31. This may represent the early development of a
severe cardiovascular phenotype or a statistical error due
to sample sizes (19 and 14, respectively).
Conclusion
Cardiovascular disease is a major cause of death and
morbidity, and significant resources are allocated to pri-
mary prevention in the general population with the aim
of reducing the overall disease burden. The same princi-
ples should apply to special groups within the population
such as patients with BBS where there is an opportu-
nity to practice personalized medicine as the genotype
of many patients is already known. This study indi-
cates that patients with missense mutations in BBS1may
be at lower risk of cardiovascular disease than patients
with homozygous truncating mutations and mutations in
BBS10. In practice most patients with BBS10 mutations
harbour the common homozygous truncating mutation
and it is possible that the resulting truncated protein prod-
uct or a hypomorphic effect of the common missense
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Fig. 3. Prevalence of cardiovascular risk factors by genotype (a) and mutation type (b). The prevalence is illustrated as a percentage to compensate for
disproportionate population sizes. Absolute numbers are given in each column.
mutation M390R in BBS1, rather than the affected gene,
determines the phenotypic effect. Larger studies could
clarify this, and longitudinal research will determine the
clinical effect these risk factors have on cardiovascular
morbidity.
Supporting Information
The following Supporting information is available for this article:
Table S1. Genotype–phenotype correlation: univariable comparison
of clinical and laboratory parameters. Patients with BBS1 vs BBS10.
Statistically significant results are highlighted in bold.
Table S2. Mutation type-phenotype comparison: univariable
comparison of clinical and laboratory parameters. Homozygous
missense, heterozygous truncating and missense and homozygous
truncating mutations. Statistically significant results are highlighted
in bold.
Table S3. Genotype–phenotype comparison: multivariable compar-
ison of selected parameters associated with cardiovascular disease.
BBS1 vs BBS10. Statistically significant results are highlighted in
bold.
Table S4. Mutation type-phenotype comparison: multivariable com-
parison of selected parameters associated with cardiovascular dis-
ease. Homozygous missense, heterozygous truncating and missense
and homozygous truncating. Statistically significant results are high-
lighted in bold.
Additional Supporting information may be found in the online
version of this article.
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